Advances of Src kinase family and paclitaxel resistance</b>

LU Lu; GUO Qinglong; ZHAO Li

doi:10.11665/j.issn.1000-5048.20170401

LU Lu, GUO Qinglong, ZHAO Li. Advances of Src kinase family and paclitaxel resistance[J]. Journal of China Pharmaceutical University, 2017, 48(4): 377-383. DOI: 10.11665/j.issn.1000-5048.20170401

Citation:

LU Lu, GUO Qinglong, ZHAO Li. Advances of Src kinase family and paclitaxel resistance[J]. Journal of China Pharmaceutical University, 2017, 48(4): 377-383. DOI: 10.11665/j.issn.1000-5048.20170401

Citation:

LU Lu, GUO Qinglong, ZHAO Li. Advances of Src kinase family and paclitaxel resistance[J]. Journal of China Pharmaceutical University, 2017, 48(4): 377-383. DOI: 10.11665/j.issn.1000-5048.20170401

Advances of Src kinase family and paclitaxel resistance

Graphical Abstract

Abstract

Abstract

Src family kinase(SFK)highly expresses in many types of cancers, broadly adjusting their malignant behaviors. Paclitaxel is a widely used chemical agent. However, because of constant resistance, the effect of paclitaxel has been greatly attenuated. The present review summaries the recent research progress of the structure and adjustment of SFK and the molecular mechanism of paclitaxel resistance, as well as the regulation of SFK on paclitaxel resistance, in order to provide new references and evidences upon the paclitaxel-based tumor therapy.

FullText(HTML)

References (86)

Supplements (0)

Cited By

Turn off MathJax

Article Contents

Advances of Src kinase family and paclitaxel resistance

Abstract

Catalog

Export File

Citation

Format

Content